EVO vs LKFT
Evotec SE and Lakefront Biotherapeutics NV, side by side — 6 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | EVO | LKFT |
|---|---|---|
| Revenue | €797.0M | €1.1B |
| Net income | €-196.1M | €320.9M |
| Gross margin | 14.4% | 97.3% |
| Net margin | −24.6% | 28.9% |
| Return on equity | −18.9% | 10.5% |
| Diluted EPS | −€1.11 | €4.87 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €-99.2M | €-271.2M |
| Equity | €952.5M | · |
| Net debt / equity | −0.02× | · |
| Current ratio | 1.98× | 20.15× |
| Revenue CAGR 5y | 12.3% | 18.4% |
| Profit CAGR 5y | · | · |
LKFT bills 1.4× the revenue of EVO, and EVO closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
6 years side by side
| Fiscal year | EVO | LKFT |
|---|---|---|
| FY2024 | €797.0M | €275.6M |
| FY2023 | €781.4M | €239.7M |
| FY2022 | €751.4M | €241.2M |
| FY2021 | €618.0M | €234.4M |
| FY2020 | €500.9M | €478.1M |
| FY2019 | €446.4M | €834.9M |
Bottom line
| Fiscal year | EVO | LKFT |
|---|---|---|
| FY2024 | €-196.1M | €74.1M |
| FY2023 | €-83.9M | €211.7M |
| FY2022 | €-175.7M | €-218.0M |
| FY2021 | €215.5M | €-103.2M |
| FY2020 | €6.3M | €-305.4M |
| FY2019 | €38.2M | €149.8M |
6 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +€521,318,000 | EVO |
| FY2023 | +€541,702,000 | EVO |
| FY2022 | +€510,199,000 | EVO |
| FY2021 | +€383,650,000 | EVO |
| FY2020 | +€22,871,000 | EVO |
| FY2019 | −€388,464,000 | LKFT |
The higher-revenue side has changed between EVO and LKFT over this period. The gap has widened since the earliest year compared.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
6 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −51.5 pp | LKFT |
| FY2023 | −99.0 pp | LKFT |
| FY2022 | +67.0 pp | EVO |
| FY2021 | +78.9 pp | EVO |
| FY2020 | +65.1 pp | EVO |
| FY2019 | −9.6 pp | LKFT |
The higher net margin has changed hands between EVO and LKFT over this period.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LKFT's net margin has been more volatile than EVO's over the 6 comparable fiscal years — 61.0 percentage points of standard deviation against 20.5.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between EVO and LKFT over these 6 fiscal years — EVO led in 3 and LKFT in 3.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
EVO's return on equity has been more volatile than LKFT's over the 6 comparable fiscal years — 13.3 percentage points of standard deviation against 7.4.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between EVO and LKFT over these 6 fiscal years — EVO led in 3 and LKFT in 3.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.